Skip to main content

Table 3 Bleeding/CVD subtypes, anti-hypertensive treatments, and anti-diabetes treatments distribution in the unmatched and coarsened exact matched cohorts

From: Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study

  Unmatched cohorts P-values Cohorts after coarsened exact matching P-value
Incident NOAC users (N = 862) Incident warfarin users (N = 626) Incident NOAC users (N = 582) Incident warfarin users (N = 486)
Prior CVD or bleeding comorbidities  
 Atrial fibrillation, n (%) 622 (72.2) 386 (61.7) < 0.0001 383 (72.5) 349 (71.8) 0.530
 Heart failure, n (%) 159 (18.5) 109 (17.4) 0.601 72 (13.6) 77 (15.8) 0.321
 Cerebrovascular disease, n (%) 177 (20.5) 112 (17.9) 0.203 106 (20.1) 79 (16.3) 0.116
 Hypertension, n (%) 584 (67.8) 409 (65.3) 0.956 337 (63.8) 311 (64.0) 0.329
 Ischemic heart disease, n (%) 239 (27.7) 170 (27.2) 0.808 130 (24.6) 120 (24.7) 0.979
 Valvular heart disease, n (%) 70 (8.1) 71 (11.3) 0.036 36 (6.8) 45 (9.3) 0.152
 Venous thromboembolism, n (%) 78 (9.1) 68 (10.9) 0.246 39 (7.4) 46 (9.5) 0.233
 Prior bleeding, n (%) 382 (44.3) 219 (35.0) < 0.0001 202 (38.3) 163 (33.5) 0.118
 Gastrointestinal bleeding, n (%) 28 (3.3) 20 (3.2) 0.954 16 (3.0) 10 (2.1) 0.328
Anti-hypertensive treatment  
 Diuretics, n (%) 365 (42.3) 252 (40.3) 0.420 215 (40.7) 190 (39.1) 0.598
 Beta-blocker, n (%) 450 (52.2) 338 (54.0) 0.495 280 (53.0) 267 (54.9) 0.543
 Calcium channel blockers, n (%) 314 (36.4) 186 (29.7) 0.006 162 (30.7) 149 (30.7) 0.427
 ARB/ACEi, n (%) 508 (58.9) 389 (62.1) 0.212 301 (57.0) 301 (61.9) 0.111
Anti-diabetes treatments
 Insulin, n (%) 122 (14.2) 97 (15.5) 0.471 63 (11.9) 64 (13.2) 0.552
 Metformin, n (%) 445 (51.6) 329 (52.6) 0.722 264 (50.0) 238 (49.0) 0.743
 Sulfonylurea, n (%) 171 (19.8) 133 (21.3) 0.506 92 (17.4) 84 (17.3) 0.953
 Thiazolidinediones, n (%) 12 (1.4) 16 (2.6) 0.103 5 (1.0) 6 (1.2) 0.659
 Dipeptidyl peptidase-4 inhibitors, n (%) 119 (13.8) 85 (13.6) 0.910 66 (12.5) 46 (9.5) 0.123
 Sodium-glucose co-transporter-2 inhibitors, n (%) 24 (2.8) 23 (3.7) 0.333 10 (1.9) 13 (2.7) 0.404
 Glucagon-like peptide 1, n (%) 12 (1.4) 12 (1.9) 0.428 6 (1.1) 5 (1.0) 0.869